Compare GRFS & AVAV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRFS | AVAV |
|---|---|---|
| Founded | 1940 | 1971 |
| Country | Spain | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Aerospace |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 14.0B |
| IPO Year | 2006 | 2007 |
| Metric | GRFS | AVAV |
|---|---|---|
| Price | $9.09 | $256.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 15 |
| Target Price | $10.15 | ★ $367.47 |
| AVG Volume (30 Days) | 556.5K | ★ 1.2M |
| Earning Date | 01-01-0001 | 12-09-2025 |
| Dividend Yield | ★ 1.57% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $8,821,017,248.00 | $1,369,870,000.00 |
| Revenue This Year | $5.46 | $148.10 |
| Revenue Next Year | $5.60 | $17.19 |
| P/E Ratio | $17.99 | ★ N/A |
| Revenue Growth | 7.31 | ★ 79.89 |
| 52 Week Low | $6.19 | $102.25 |
| 52 Week High | $11.14 | $417.86 |
| Indicator | GRFS | AVAV |
|---|---|---|
| Relative Strength Index (RSI) | 55.45 | 43.43 |
| Support Level | $8.69 | $227.47 |
| Resistance Level | $9.22 | $240.29 |
| Average True Range (ATR) | 0.19 | 13.36 |
| MACD | 0.04 | 1.09 |
| Stochastic Oscillator | 77.60 | 42.77 |
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
AeroVironment Inc supplies unmanned aircraft systems, tactical missile systems, high-altitude pseudo-satellites, and other related services to government agencies within the United States Department of Defense as well as the United States allied international governments. The systems can help with security, surveillance, or sensing, and provide eyes in the sky without needing an actual person, or driver in the sky. The company is a defense technology provider delivering integrated capabilities across air, land, sea, space, and cyber. It develops and deploy autonomous systems, precision strike systems, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities. Company operates in three segments: UxS, LMS, MW.